Major drug study tracks safety of new hair loss treatment
NCT ID NCT07152119
Summary
This study is monitoring the safety and effectiveness of Litfulo capsules in real-world patients with severe alopecia areata (an autoimmune condition causing significant hair loss). It will enroll 3,000 patients in Korea who are already prescribed the medication to track side effects and see how well it helps regrow hair over time. The goal is to better understand the medicine's safety profile and benefits after it has been approved for use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer, Inc
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.